Furthermore, elevated TNF-α levels are consistently observed in COVID-19 patients with comorbidities such as obesity, hypertension, and cardiovascular disease (CVD), where it fuels heightened inflammation, endothelial dysfunction, increased thrombosis risk, and atherosclerotic plaque destabilization, elevating the risk of acute cardiovascular events [132]. This evidence concerns the gene TNF and COVID-19.